CALC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 41.55%

Insider Buying (Last 12 Months): $1,229,000.89

Insider Selling (Last 12 Months): $0.00

CalciMedica Insider Trading History Chart

CalciMedica Share Price & Price History

^$1.83

▼ -0.1191 (-6.11%)

As of 04/2/2025 04:15 PM ET

Days: 30 | 90 | 365

CalciMedica Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/6/2024	Fred A Middleton	Director	Buy	4,800	$2.65	$12,720.00	36,514
11/1/2024	A. Rachel Leheny	CEO	Buy	20,000	$3.75	$75,000.00	130,926
11/1/2024	Eric W Roberts	Insider	Buy	53,333	$3.75	$199,998.75	164,706
11/1/2024	Fred A Middleton	Director	Buy	87,744	$3.75	$329,040.00	814,300
11/1/2024	Sanderling Venture Partners Vi	Major Shareholder	Buy	86,867	$3.75	$325,751.25	814,300
8/27/2024	A. Rachel Leheny	CEO	Buy	1,000	$4.19	$4,190.00	110,926
8/23/2024	Eric W Roberts	Insider	Buy	5,000	$3.57	$17,850.00	46,894
8/23/2024	Robert N Wilson	Director	Buy	54,000	$3.72	$200,880.00	364,196
8/21/2024	Eric W Roberts	Insider	Buy	5,000	$4.04	$20,200.00	44,894
6/27/2024	Eric W Roberts	Insider	Buy	5,000	$3.22	$16,100.00	10,223
6/27/2024	Robert N Wilson	Director	Buy	8,443	$3.23	$27,270.89	258,918
4/1/2024	Eric W Roberts	Insider	Buy	746	$3.90	$2,909.40	36,640
1/23/2024	Fred A Middleton	Director	Buy	679,384	$3.70	$2,513,720.80	946,744
1/23/2024	Sanderling Venture Partners Vi	Major Shareholder	Buy	243,356	$3.70	$900,417.20	946,744
12/11/2023	Robert N Wilson	Director	Buy	506	$3.30	$1,669.80	182,161
11/6/2023	A. Rachel Leheny	CEO	Buy	2,440	$3.12	$7,612.80	16,840
11/6/2023	Eric W Roberts	Insider	Buy	2,400	$3.12	$7,488.00	35,894
11/3/2023	A. Rachel Leheny	CEO	Buy	5,000	$2.85	$14,250.00	14,400
11/3/2023	Eric W Roberts	Insider	Buy	3,200	$2.80	$8,960.00	16,587
8/25/2023	Eric W Roberts	Insider	Buy	736	$3.18	$2,340.48	5,000
8/21/2023	Eric W Roberts	Insider	Buy	1,750	$3.25	$5,687.50	3,550
6/26/2023	Eric W Roberts	Insider	Buy	1,200	$3.70	$4,440.00	13,387
6/23/2023	Eric W Roberts	Insider	Buy	500	$3.35	$1,675.00	16,185

See Full Table

SEC Filings (Institutional Ownership Changes) for CalciMedica (NASDAQ:CALC)

Institutional Buying and Selling by Quarter

CalciMedica Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/12/2025	Wealthedge Investment Advisors LLC	27,819	$98K	0.0%	N/A	0.206%
2/17/2025	Stonepine Capital Management LLC	468,793	$1.66M	1.3%	N/A	3.478%
2/17/2025	Millennium Management LLC	72,057	$0.26M	0.0%	+30.5%	0.535%
2/17/2025	Deerfield Management Company L.P. Series C	1,300,000	$4.60M	0.1%	+30.0%	9.644%
2/17/2025	Cetera Investment Advisers	16,873	$60K	0.0%	+37.1%	0.125%
2/17/2025	Alyeska Investment Group L.P.	372,256	$1.32M	0.0%	N/A	2.762%
2/13/2025	Renaissance Technologies LLC	43,200	$0.15M	0.0%	N/A	0.320%
2/12/2025	Geode Capital Management LLC	90,866	$0.32M	0.0%	+36.5%	0.674%
2/10/2025	Corient Private Wealth LLC	38,000	$0.14M	0.0%	N/A	0.282%
2/6/2025	Atria Investments Inc	34,012	$0.12M	0.0%	+28.3%	0.252%
11/25/2024	PVG Asset Management Corp	15,115	$67K	0.3%	N/A	0.112%
11/16/2024	Geode Capital Management LLC	66,553	$0.30M	0.0%	+51.2%	0.619%
11/5/2024	BML Capital Management LLC	153,887	$0.68M	0.4%	-4.1%	1.432%
11/1/2024	Atria Investments Inc	26,503	$0.12M	0.0%	+136.5%	0.247%
4/23/2024	BML Capital Management LLC	160,424	$0.67M	0.4%	+10.3%	1.494%
2/2/2024	Meritage Portfolio Management	46,000	$0.13M	0.0%	+360.0%	0.810%
1/30/2024	BML Capital Management LLC	145,424	$0.42M	0.3%	+63.8%	2.560%
12/7/2023	Hudson Bay Capital Management LP	166,857	$0.43M	0.0%	N/A	2.938%
7/31/2023	Meritage Portfolio Management	10,000	$40K	0.0%	N/A	0.177%
7/24/2023	BML Capital Management LLC	88,781	$0.36M	0.3%	N/A	1.568%

Data available starting January 2016

See Full Table

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Today's Range

Now: $1.83

$1.83

$1.95

50 Day Range

MA: $2.34

$1.90

$2.94

52 Week Range

Now: $1.83

$1.81

$6.27

Volume

6,578 shs

Average Volume

44,318 shs

Market Capitalization

$24.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Who are the company insiders with the largest holdings of CalciMedica?: CalciMedica's top insider investors include:
Fred A Middleton (Director)
Sanderling Venture Partners Vi (Major Shareholder)
Robert N Wilson (Director)
Eric W Roberts (Insider)
A Rachel Leheny (CEO)
Learn More about top insider investors at CalciMedica.